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ABSTRACT 28 
The anterior cruciate ligaments are susceptible to degeneration, resulting in pain, 29 
reduced mobility and development of the degenerative joint disease osteoarthritis. 30 
There is currently a paucity of knowledge on how anterior cruciate ligament 31 
degeneration and disease can lead to osteoarthritis. Small non-coding RNAs 32 
(sncRNAs), such as microRNAs, and small nucleolar RNA, are important regulators 33 
of gene expression. We aimed to identify sncRNA profiles of human anterior cruciate 34 
ligaments to provide novel insights into their roles in osteoarthritis. 35 
RNA was extracted from the anterior cruciate ligaments of non-osteoarthritic knee 36 
joints (control) and end-stage osteoarthritis knee joints, used for small RNA 37 
sequencing and significantly differentially expressed sncRNAs defined. Bioinformatic 38 
analysis was undertaken on the differentially expressed miRNAs and their putative 39 
target mRNAs to investigate pathways and biological processes affected.   40 
Our analysis identified 184 sncRNA that were differentially expressed between control 41 
ACLs derived from osteoarthritic joints with a false discovery adjusted p value<0.05; 42 
68 small nucleolar RNAs, 26 small nuclear RNAs and 90 microRNAs. We identified 43 
both novel and previously identified (miR-206, -101, -365 and -29b and -29c) 44 
osteoarthritis-related microRNAs and other sncRNAs (including SNORD74, 45 
SNORD114, SNORD72) differentially expressed in ligaments derived from 46 
osteoarthritic joints. Significant cellular functions deduced by the differentially 47 
expressed miRNAs included differentiation of muscle (P<0.001), inflammation 48 
(P<1.42E-10), proliferation of chondrocytes (P<0.03), fibrosis (P<0.001) and cell 49 
viability (P<0.03). Putative mRNAs were associated with the canonical pathways 50 
‘Hepatic Fibrosis Signalling’ (P<3.7E-32), and ‘Osteoarthritis’ (P<2.2E-23).  Biological 51 
processes included apoptosis (P<1.7E-85), fibrosis (P<1.2E-79), inflammation 52 
(P<3.4E-88), necrosis (P<7.2E-88) and angiogenesis (P<5.7E-101).  53 
SncRNAs are important regulators of anterior cruciate disease during osteoarthritis 54 
and may be used as therapeutic targets to prevent and manage anterior cruciate 55 
ligament disease and the resultant osteoarthritis.  56 
 57 
 58 
INTRODUCTION 59 
Ligaments are resilient connective tissues essential for bone-to-bone connections 60 
within joints [1]. The anterior cruciate ligament (ACL) is the most commonly damaged 61 
ligament [2] with an incidence of approximately 68.6 ACL ruptures per 100,000 people 62 
[3] resulting in considerable social and economic costs [4, 5].  In the USA alone, there 63 
are approximately 100,000-175,000 ACLs surgeries per year, with cost exceeding of 64 
2 billion dollars [6, 7]. ACL injuries can also lead to significant functional impairment in 65 
athletes, muscle atrophy and weakness, joint instability, meniscal lesions, and are 66 
associated with development of osteoarthritis (OA) [8, 9]. In the case of the knee joint, 67 
more than 50% of ACL injury patients eventually develop OA with the degree and 68 
progression of disease being accelerated in these cases [10, 11]. Reports 69 
demonstrate that there is an association between ACL degeneration and subsequent 70 
knee OA, suggesting the importance of ACL degradation in OA pathogenesis [12].  71 
 72 
There is currently substantial interest in the area of epigenetic regulation in ageing, 73 
disease, and repair mechanisms in musculoskeletal tissues such as muscle [13, 14], 74 
cartilage [15, 16], tendon [17, 18] and ligament [19, 20]. Epigenetics is the study of 75 
changes in gene expression that do not derive from changes to the genetic code itself 76 
[21]. Insufficient exploration of the epigenetic changes in diseased ACL has been 77 
undertaken. One class of epigenetic molecules are small non-coding RNAs (sncRNAs) 78 
which   include microRNAs (miRNAs or miRs), small nucleolar RNAs (snoRNAs) and 79 
small nuclear RNAs (snRNAs) These are functional RNA molecules that are 80 
transcribed from DNA but do not translate into proteins and are emerging as important 81 
regulators of gene expression before and after protein transcription. Their aberrant 82 
expression profiles in musculoskeletal conditions such as ACL injury are expected to 83 
be associated with cellular dysfunction and disease development [22]. We have 84 
previously identified changes in the sncRNA profiles in ageing and OA human and 85 
equine cartilage [16, 23, 24], ageing human and equine tendon [25, 26] and ageing 86 
and OA murine joints and serum [27]. Identifying sncRNAs associated with ACL 87 
degradation and comprehending their role in OA could have an enormous impact on 88 
the understanding of its pathogenesis and future management. 89 
 90 
To date, little is known about the sncRNA changes in diseased ACL. We hypothesise 91 
that sncRNA expression is altered in ACLs derived from OA joints and that their 92 
identification may elucidate the underlying mechanisms of ACL degeneration. This 93 
information could then provide potential diagnostic markers and enable future 94 
therapeutic targets to treat ACL degeneration, facilitating prompt positive intervention 95 
in the associated development of OA.   96 
 97 
MATERIALS AND METHODS 98 
All reagents were from ThermoFisher Scientific, unless otherwise stated. 99 
Sample collection  100 
ACLs from non-OA, apparently healthy knee joints (control) (n=4) were obtained from 101 
a commercial biobank (Articular Engineering). Ethical approval for the purchase 102 
human ACL tissue was granted by the Central University Research Ethics Committee 103 
C, University of Liverpool (RETH4721). Diseased OA ACLs were obtained from the 104 
knee joints of patients undergoing total knee arthroplasty for end-stage OA treatment 105 
(n=4). Fully informed patient consent was given for the use of these samples under 106 
the institutional ethical approval (Maastricht University Medical Centre approval IDs: 107 
MUMC 2017-0183). Samples were collected in RNAlater and stored at -80°C until 108 
used. 109 
 110 
RNA extraction 111 
RNA was extracted from ACL tissues once pulverised into a powder with a 112 
dismembranator (Mikro-S, Sartorius, Melsungen, Germany) under liquid nitrogen.  113 
Total RNA was extracted using the miRNeasy kit (Qiagen, Manchester, UK) according 114 
to the manufacturer's instructions. The RNA samples were quantified using a 115 
Nanodrop spectrophotometer (NanoDrop Technologies, Wilmington, USA). The 116 
integrity of the RNA was assessed on the Agilent 2100 Bioanalyzer (Agilent, Stockport, 117 
UK) using an RNA Pico chip (Agilent, Stockport, UK). 118 
 119 
Small RNA-Sequencing analysis: cDNA library preparation and sequencing  120 
1000ng RNA per sample  was submitted for library preparation using NEBNext® Small 121 
RNA Library Prep Set for Illumina (New England Biosciences (NEB), Ipswich, USA) 122 
but with the addition of a Cap-Clip™ Acid Pyrophosphatase (Cell script, Madison, 123 
USA) step to remove any 5’ cap structures on some snoRNAs [27] and size selected 124 
using a range 120-300bp (including adapters). This enabled both miRNAs and 125 
snoRNAs to be identified using a non-biased approach. The pooled libraries were 126 
sequenced on an Illumina HiSeq4000 platform with version 1 chemistry to generate 2 127 
x 150 bp paired-end reads.  128 
 129 
Data processing 130 
Sequence data were processed through a number of steps to obtain non-coding RNA 131 
expression values including; basecalling and de-multiplexing of indexed reads using 132 
CASAVA version 1.8.2; adapter and quality trimming using Cutadapt version 1.2.1 [28] 133 
and Sickle version 1.200 to obtain fastq files of trimmed reads; aligning reads to human 134 
genome reference sequences (release 95) from Ensembl using Tophat version 2.0.10 135 
[29] with option “–g 1”; counting aligned reads using HTSeq-count [30] against the 136 
features defined in human genome GTF file (release 95). The features whose biotype 137 
belonged to the gene categories such as miRNA, snoRNA, and snRNA were 138 
extracted.  139 
Differential expression (DE) analysis was performed in R using package DESeq2 [31]. 140 
The processes and technical details of the analysis include; assessing data variation 141 
and detecting outlier samples through comparing variations of within and between 142 
sample groups using principle component analysis (PCA) and correlation analysis; 143 
handling library size variation using DESeq2 default method; formulating data variation 144 
using negative binomial distributions; modelling data using a generalised linear model; 145 
computing log fold change (logFC) values for control versus OA ACLs based on model 146 
fitting results through contrast fitting approach, evaluating the significance of estimated 147 
logFC values by Wald test; adjusting the effects of multiple tests using false discovery 148 
rate (FDR) [32] approach  to obtain FDR adjusted P-values. 149 
 150 
Pathway analysis of differentially expressed miRNAs and their predicted targets 151 
Potential biological associations of the DE miRNAs in OA ACL were identified using 152 
Ingenuity Pathway Analysis (IPA) (IPA, Qiagen Redwood City, USA) ‘Core Analysis’. 153 
Additionally in order to identify putative miRNA targets, bioinformatic analysis was 154 
performed by uploading DE miRNA data into the MicroRNA Target Filter module within 155 
IPA. This identifies experimentally validated miRNA-mRNA interactions from TarBase, 156 
miRecords, and the peer-reviewed biomedical literature, as well as predicted miRNA-157 
mRNA interactions from TargetScan. We applied a conservative filter at this point, 158 
using only experimentally validated and highly conserved predicted mRNA targets for 159 
each miRNA. Targets were also filtered on the cells fibroblasts and mesenchymal stem 160 
cells (as these were closest to potential cell types within ligament). ‘Core Analysis’ was 161 
then performed in IPA on the filtered mRNA target genes and their associated 162 
miRNAs. For each core analysis canonical pathways, novel networks, diseases and 163 
functions, and common upstream regulators were queried.  164 
 165 
Additionally TOPP Gene [33] was used for overrepresentation analysis of the mRNA 166 
targets from Target Filter using Fisher’s Exact test with FDR correction. This tests 167 
whether the input mRNAs associate significantly with specific pathways and generates 168 
a list of biological process gene ontology (GO) terms. Terms with FDR adjusted P < 169 
0.05 were summarised using REViGO [34] with allowed similarity of 0.4 and visualised 170 
using Cytoscape [35]. 171 
 172 
Statistical analysis 173 
The heatmap,  volcano and principle component analysis (PCA) plots were made 174 
using MetaboAnalyst 3.5 (http://www.metaboanalyst.ca) which uses the R package of 175 
statistical computing software.30 [36]. 176 
 177 
RESULTS 178 
Sample assessment 179 
The ages of the control group (age, mean ± standard deviation (48 ± 2.16)) and ACLs 180 
derived from OA joints (74.7 ± 5.42) were significantly different (p<0.05) 181 
(Supplementary Figure 1). Summary of all donors’ information is provided in 182 
Supplementary Table 1.  183 
 184 
Analysis of small RNA sequencing data 185 
We identified a total 590 miRNAs, 226 snoRNAs and 100 small nuclear (snRNAs) in 186 
the samples (with greater than 10 counts per million (CPM) in each samples). There 187 
were 184 differentially expressed sncRNAs identified (FDR<0.05) and at least 10 CPM 188 
in each sample. The categories of RNA identified are in Figure 1A and included 189 
miRNAs, snoRNAs and small nuclear RNAs (snRNAs). PCA revealed that the ACLs 190 
derived from non-OA joints (control) were clustered together and could be clearly 191 
separated from the ACLs derived from OA knee joints (Figure 1B). 192 
 193 
Of the 184 snRNAs there were 68 DE snoRNAs (64 reduced in OA and 4 increased 194 
in OA), 26 DE snRNAs (24 reduced in OA and 2 increased in OA) and 90 DE miRNAs 195 
(43 reduced in OA and 47 increased in OA) (FDR<0.05 and greater than 10 CPM in 196 
all samples) (Figure 1C, Supplementary Table 2). The most DE miRNAs are in Table 197 
1, with snRNA and snoRNAs in Table 2. We further generated a heatmap of the DE 198 
sncRNAs for miRNAs (Figure 1D) and snRNAs and snoRNAs (Supplementary Figure 199 
2). 200 
 201 
Pathway analysis of differentially expressed miRNAs 202 
To explore potential biological associations of the 90 DE miRNAs in ACLs derived from 203 
OA knee joints we undertook an IPA ‘Core Analysis’. Network-eligible molecules were 204 
overlaid onto molecular networks based on information from Ingenuity Pathway 205 
Knowledge Database. Networks were then generated based on connectivity. 206 
Interesting features were determined from the gene networks inferred. Significant 207 
cellular functions deduced by the DE miRNAs included differentiation of muscle 208 
(P<0.001), inflammation (P<1.42E-10), proliferation of chondrocytes (P<0.03), fibrosis 209 
(P<0.001) and cell viability (P<0.03) (Figure 2A). The top scoring network identified 210 
was ‘Organismal Injury and Abnormalities’ (score 43) and included OA-related 211 
miRNAs such as miR-206, miR-101, let-7f, miR-455, miR-29b and miR-29c (Figure 212 
2B).  213 
 214 
Pathway analysis on target mRNA genes of the differentially expressed miRNAs 215 
Next, we undertook analysis to determine the mRNA targets of the DE miRNAs. 90 216 
miRNAs that were DE in ACLs derived from OA knee joints compared to controls were 217 
initially input into MicroRNA Target Filter. Once a conservative filter was applied (only 218 
miRNAs with experimental or highly predicted targets), 529 mRNAs were putative 219 
targets (Supplementary Table 3). These mRNAs were then input into IPA core analysis 220 
and all results summarised in Supplementary Table 3. The top canonical pathways for 221 
target mRNAs of DE miRNAs in OA ACL are in Table 3. Two of the most significant of 222 
which were the osteoarthritis pathway (P<2.3E-23) and hepatic fibrosis (P<3.1E-32) 223 
(Figure 3). The most significant upstream regulators of these mRNAs included tumour 224 
necrosis factor (P<1.3E-101) and transforming growth factor β (TGFβ) (P<8.5E-83) 225 
(Table 4). Upstream regulators represent molecules that may be responsible for the 226 
putative mRNAs in our dataset and cover the gamut of molecule types found in the 227 
literature, from transcription factors, to cytokines, chemicals and drugs. The most 228 
significant diseases and biological functions identified are shown in Table 5. The top 229 
networks identified are in Supplementary Table 3. The network ‘cellular development, 230 
movement and genes expression’ (score 41) (Figure 4A) was overlaid with significant 231 
biological processes including apoptosis (P<1.7E-85), fibrosis (P<1.2E-79), 232 
inflammation (P<3.4E-88), and necrosis (P<7.2E-88). The network ‘inflammatory 233 
disease’ (score 35) (Figure 4B) shows pertinent significant biological processes 234 
including organisation of collagen fibrils (P<3.7E-07), fibrosis (P<2.6E-14), rheumatoid 235 
arthritis (P<3.6E-06), angiogenesis (P<8.9E-09), differentiation of bone (P<5E-06), 236 
inflammation of the joint (P<8.8E-07) and cartilage development (1.5E-07).  237 
 238 
To obtain an overview of pathways that the putative target mRNAs were involved in 239 
the mRNAs derived from IPA were also input into the gene ontology (GO) tool TOPP 240 
Gene and the biological processes summarised in REViGO and visualised using 241 
Cytoscape (Figure 5 and Supplementary Table 4). 242 
 243 
 244 
DISCUSSION 245 
The global prevalence of knee OA is currently 5% and is projected to rise with an 246 
increase in the ageing population [37]. Reports propose that there is an association 247 
between ACL degeneration and subsequent knee OA, suggesting the importance of 248 
ACL degradation and regeneration molecular mechanisms in OA pathogenesis [38]. 249 
There is also a strong correlation between ACL degeneration and subsequent knee 250 
OA [12]. One potential mechanism capable of regulating global alterations to a 251 
particular tissue is modification of sncRNA expression. To begin to elucidate the role 252 
that they play in the global changes observed in the ACL during OA and understand 253 
further the potential role of the ACL in arthritis, we undertook a non-biased approach 254 
small RNA sequencing of ACLs from OA knee joints and compared these to our control 255 
samples derived from non-OA knee joints. Whilst a study previously demonstrated DE 256 
miRNAs in ACL [20], this is the first time that, to our knowledge, small RNA sequencing 257 
has been used to interrogate both snoRNAs and miRNAs in an unbiased manner and 258 
we identified unique OA dependant signatures.  259 
 260 
 There were 68 snoRNAs, 26 snRNAs and 90 miRNAs significantly different in ACLs 261 
derived from OA knee joints and the OA status of the donor accounted for the principal 262 
variability in the data. Additional bioinformatics was performed, to analyse the 263 
biological processes and pathways affected by the differentially expressed miRNAs 264 
and in addition, the putative mRNA targets of the differentially expressed miRNAs, 265 
enhancing our understanding of the roles of the dysregulated miRNAs in OA 266 
pathogenesis.  267 
 268 
Several of DE miRNAs found in this study, including miR-29b, miR -335, let-7f, miR-269 
424, and miR-941 correlate to previously altered miRNAs in a study comparing 270 
ruptured ACLs to diseased  OA ACLs [20]. These miRNAs were found to be correlated 271 
with cartilage development and remodelling, extracellular matrix homeostasis and 272 
inflammatory response [20]. We have found other miRNAs associated with OA 273 
including miR-206, miR-101, miR365, miR-29b and miR-29c, whose expression 274 
altered in ACLs derived from OA joints [39-41]. Pathways identified by the DE miRNAs 275 
with known functions in OA in other tissues included inflammation [42], proliferation of 276 
chondrocytes [43], and fibrosis [44]. Canonical pathways identified have roles in OA 277 
pathogenesis including senescence [45],  fibrosis, TGFβ signalling  [46], retinoic acid 278 
binding protein (RAR) activation [47] and peroxisome proliferator-activated 279 
receptor/retinoid X receptor (PPAR/RXR) activation  [48, 49]. 280 
  281 
To address the roles of miRNAs in diseased OA ACLs, their mRNA target genes 282 
should also be taken into consideration. Therefore, in order to determine potential 283 
mRNA targets of the DE miRNAs we used Target Filter in IPA to identify predicted 284 
mRNA targets. We used conservative filters for the mRNAs identified by only choosing 285 
highly conserved predicted mRNA targets for each miRNA and by choosing relevant 286 
cell types to ACL tissue. We then undertook GO analysis and visualisation of the 287 
significant biological processes effected with online tools. Using ToppGene, Revigo 288 
and Cytoscape for visualisation, we showed an overview of the essential biological 289 
processes these mRNA target genes were involved in, including extracellular matrix 290 
organisation, epigenetic regulation, cell signalling, cell growth and proliferation. In IPA, 291 
additional functions affected by these genes, known to have a role in OA pathogenesis 292 
and therefore with a potential role in OA ACLs were highlighted including apoptosis 293 
[50], fibrosis [44], inflammation of the joint [42], necrosis [51], organisation of collagen 294 
fibrils [12], angiogenesis [52], differentiation of bone [53] and cartilage development 295 
[54]. Canonical pathway analysis was also performed. We found that many pathways 296 
enriched by the putative target genes were essential for OA pathogenesis, including 297 
the ‘osteoarthritis pathway’. The significant mRNA targets in this pathway included 298 
those involved in inflammation (TNF, IL1, IL8), Wnt signalling (WNt3A, Frizzled, 299 
TCF/LEF), TGFβ and SMAD signalling (TGFβR2, SMAD1, -4, -5, -8), hypoxia (HIF1α), 300 
and mammalian target of rapamycin signalling (MTOR). Additionally downstream 301 
targets of these signalling pathways with known roles in OA pathogenesis were 302 
identified and included matrix metalloproteinase-3 [55], tissue inhibitor of 303 
metalloproteinase- 3 [56], and collagen X α1 [57]. These findings indicate the potential 304 
importance of these pathways in ACL degeneration associated with OA.  Hepatic 305 
fibrosis was the most significant canonical pathway identified from the putative 306 
mRNAS together with the DE miRNAs in our study. Synovial fibrosis is often found in 307 
OA [44] and fibrosis has previously been described in OA joints following ACL injury 308 
[58]. Furthermore TGFβ, one of the most significant upstream regulator in our mRNA 309 
target gene analysis,  is the master regulator of fibrosis [57]. Many TGFβ-related genes 310 
including TGFβ2, TGFβ3, TGFβR1, TGFβR2 and TGFβR3 were predicted targets of 311 
the DE miRNAs including miR-98-5p, miR-101-3p, miR-128-5p, miR-136-3p, miR-17-312 
5p; strongly implicating it in the fibrosis evident in the diseased ACLs in OA.  313 
 314 
Another class of snRNAs, snoRNAs, were altered in the OA ACLs in our study. This 315 
conserved class of non-coding RNAs are principally characterised as guiding site-316 
specific post-transcriptional modifications in ribosomal RNA [59]. Furthermore 317 
snoRNAs can modify and/or interact with additional classes of RNAs including other 318 
snoRNAs, transfer RNAs and mRNAs [60]. A reliable modification site has been 319 
assigned to 83% of the canonical snoRNAs, with 76 snoRNAs described as orphan, 320 
meaning they act in an unknown or unique manner [61]. Novel functions reported for 321 
snoRNAs including the modulation of alternative splicing [62], involvement in stress 322 
response pathways, [63] and the modulation of mRNA 3′end processing [64]. Like 323 
miRNAs, snoRNAs are emerging as important regulators of cellular function and 324 
disease development [65], in part due to their ability to fine-tune the ribosome to 325 
accommodate changing requirements for protein production during development, 326 
normal function and disease [66] . 327 
 328 
We have previously identified a role for snoRNAs in cartilage ageing and OA [24] and 329 
their potential use as biomarkers for OA [27]. Furthermore, others identified that the 330 
snoRNAs, SNORD38 and SNORD48, are significantly elevated in the serum of 331 
patients developing cartilage damage a year following ACL injury and serum levels of 332 
SNORD38 were greatly elevated in patients who develop cartilage damage after ACL 333 
injury suggesting SNORD38 as a serum biomarker for early cartilage damage [67] 334 
 335 
Interestingly, we found an increase in SNORD113 and SNORD114 in diseased OA 336 
ACLs. These snoRNAs are located in imprinted human loci and may play a role in the 337 
evolution and/or mechanism of epigenetic imprinting [61].They belong to the C/D box 338 
class of snoRNAs and most of the members of the box C/D family direct site-specific 339 
2'-O-methylation of substrate RNAs. However, SNORD113 and SNORD114 differ 340 
from C/D box snoRNAs in their tissue specific expression profiles (including in 341 
fibroblasts, osteoblasts and chondrocytes [61] and the lack of complementarity to any 342 
RNA. As a result, they are not predicted to guide to 2'O-methylation but have novel, 343 
unknown roles [61]. Additionally SNORD113-1 functions as a tumour suppressor in 344 
hepatic cell carcinoma by reducing cell growth and inactivating the phosphorylation of 345 
ERK1/2 and SMAD2/3 in MAPK/ERK and TGF-β pathways [68]. We have previously 346 
identified that SNORD113-1  is also increased in OA human knee cartilage but 347 
reduced in ageing human knee cartilage, whilst SNORD114 increases in OA knee 348 
cartilage [24].  349 
 350 
SNORD72 was increased in diseased OA ACLs. In hepatocellular carcinoma, the 351 
overexpression of SNORD72 was found to enhance cell proliferation, colony formation 352 
and invasion by stabilising Inhibitor of differentiation (ID) genes which are a basic helix-353 
loop-helix (bHLH) transcription factors [69]. The ID family genes have been shown to 354 
play a role in cell proliferation and angiogenesis [70]. The lack of a DNA binding 355 
domain, results in inhibition of the binding of other transcription factors  to  DNA   in   a   356 
dominant   negative   fashion [71]. The expression of some members of this family in 357 
rheumatoid arthritis synovium suggests they may have a role in human inflammatory 358 
disease [72].  Whilst the   downstream   signalling   of snoRNAs    is    principally   359 
unknown,    snoRNAs   regulate ribosome biogenesis [73]. However a   subclass of  360 
orphans do not have complimentary RNA  sequences [74].  Mao Chet et al., found that 361 
ribosome biogenesis was not affected following SNORD72 overexpression implying   362 
it  exerts functionality in other ways [69]. Therefore whilst some snoRNAs can regulate  363 
the  expression  of  RNAs [75],  others can  reduce  the  gene stability [74]  or   directly  364 
activate  or  suppress  enzymes [76].  Together our snoRNA findings indicate that 365 
changes in ACL snoRNA expression could have important implications in knee OA 366 
through both canonical and non-canonical roles. 367 
  368 
Our study has a number of limitations due to availability of human ACL tissue.  There 369 
was also a mild imbalance between the sexes in the two groups with most of the OA 370 
derived ACLs coming from males but all the control group being sourced from females. 371 
In human tendon, we have previously demonstrated that males and females are 372 
transcriptionally different and gene expression in aged cells moves in opposite 373 
directions [26].  Ligament degeneration  has also been demonstrated to be influenced 374 
by lower concentrations of sex hormones in young female athletes [77]. Macroscopic 375 
grading of tissues were not performed due to limited images of diseased OA ACL 376 
samples, however images of control samples demonstrated healthy knee joint 377 
cartilage with no signs of ACL degeneration. Finally, there were age discrepancies 378 
between the two groups and so we cannot discount an age effect on sncRNAs 379 
expression. 380 
 381 
In conclusion, our study revealed alterations in a number of classes of snRNAs in ACL 382 
tissues derived from patients with knee OA compared to apparently healthy ACLs from 383 
non-OA joints. Our functional bioinformatic analyses suggests that the dysregulated 384 
miRNAs may regulate cartilage development and remodelling, collagen biosynthesis 385 
and degradation, ECM homeostasis and pathology by interacting with their targets. 386 
Uniquely we also demonstrate that snoRNAs may also have a role in ACL 387 
degeneration. Collectively, our study provides novel insight into the ACL related 388 
sncRNA dysregulation in patients with OA. 389 
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 618 
Table 1. Differentially expressed miRs with the highest and lowest log2 fold-change 619 
when comparing from control versus diseased OA anterior cruciate ligament (ACL).  620 
 621 
miR  Log2 fold-
change 
FDR adjusted 
p-values 
Genes with increased expression in diseased 
OA ACL  
 
hsa-miR-5100 3.75 6.2E-07 
hsa-miR-31-5p 3.14 6.9E-15 
hsa-miR-129-5p 2.42 4.0E-03 
hsa-miR-144-3p 2.41 3.5E-04 
hsa-miR-486-5p 2.33 3.2E-04 
hsa-miR-370-3p 2.32 1.4E-06 
hsa-miR-543 2.20 6.3E-03 
hsa-miR-4521 2.19 5.1E-04 
hsa-miR-493-5p 2.17 6.7E-04 
hsa-miR-411-3p 2.16 3.9E-03 
Genes with reduced expression in control ACL   
hsa-miR-206 -6.13 1.9E-06 
hsa-miR-12136 -4.35 3.3E-18 
hsa-miR-3182 -3.20 3.8E-10 
hsa-miR-101-5p -2.22 9.6E-03 
hsa-miR-338-3p -2.08 1.5E-02 
hsa-miR-335-5p -2.03 7.3E-03 
hsa-miR-190b-5p -1.98 2.5E-03 
hsa-miR-29c-3p -1.89 1.1E-02 
hsa-miR-103a-5p -1.86 3.7E-06 
hsa-miR-30b-5p -1.81 1.7E-02 
 622 
 623 
 624 
 625 
 626 
 627 
Table 2. Small-non coding RNAs (small nucleolar RNAs (snoRNAs) and small nuclear 628 
RNA (sncRNA) identified as differentially expressed between control and anterior 629 
cruciate ligaments (ACLs) derived from osteoarthritic joints.  630 
Name Family  Action Log2 
fold-
change 
FDR adjusted 
p- value 
Higher 
SNORD114 
 
C/D BOX Site-specific 2’-O-methylation 3.60 
 
4.7E-07 
 
OA 
ACL 
SNORD113 C/D BOX Site-specific 2’-O-methylation 2.85 
 
9.8E-05 
 
OA 
ACL 
RNU6 Splicesome Complex of snRNA and protein 
subunits that removes introns 
from a transcribed pre-mRNA 
2.85 
 
4.8E-03 
 
OA 
ACL 
SNORD72 C/D BOX Site-specific 2’-O-methylation 1.83 
 
4.2E-02 
 
OA 
ACL 
RNVU1-19 Splicesome Complex of snRNA and protein 
subunits that removes introns 
from a transcribed pre-mRNA 
1.58 
 
4.8E-02 OA 
ACL 
RNU7-19P Splicesome Complex of snRNA and protein 
subunits that removes introns 
from a transcribed pre-mRNA 
-7.61 4.0E-07 
 
Control 
ACL 
RNU4-59P 
 
Splicesome Complex of snRNA and protein 
subunits that removes introns 
from a transcribed pre-mRNA 
-4.90 
 
1.4E-33 
 
Control  
ACL 
SNORA36B 
 
H/ACA box H/ACA family of 
pseudouridylation guide 
snoRNAs 
-4.25 
 
2.7E-06 
 
Control  
ACL 
SNORA53 
 
H/ACA box H/ACA family of 
pseudouridylation guide 
snoRNAs 
-3.68 
 
5.1E-15 Control  
ACL 
SNORA73B 
 
H/ACA box H/ACA family of 
pseudouridylation guide 
snoRNAs 
-3.61 
 
3.9E-05 Control  
ACL 
 631 
  632 
Table 3. Top canonical pathways for target mRNAs of differentially expressed miRNAs 633 
in diseased OA anterior cruciate ligaments (ACLs).  634 
Name         p-value   Overlap 635 
Hepatic Fibrosis Signalling Pathway    1.62E-33   15.8 % 636 
  637 
Hepatic Fibrosis/Hepatic Stellate Cell Activation   3.06E-32   23.1 % 638 
  639 
Cardiac Hypertrophy Signalling      1.28E-28   12.3 % 640 
  641 
Colorectal Cancer Metastasis Signalling    1.97E-27   17.4 % 642 
  643 
Role of Macrophages, Fibroblasts and Endothelial Cells  2.32E-27   15.4 %  644 
 645 
  646 
Table 4. Top upstream regulators of differentially expressed miRNAs in diseased OA 647 
anterior cruciate ligaments (ACLs). 648 
Name       p-value  649 
Tumour necrosis factor   1.31E-101 650 
Transforming growth factor B1   8.50E-83 651 
lipopolysaccharide     1.14E-81 652 
Interleukin 1B     1.45E-77 653 
tretinoin      9.26E-77654 
Figure legends  
Figure 1. Overview of HiSeq transcriptomics data between control and diseased 
osteoarthritic (OA) human anterior cruciate ligament (ACL). A. Categories of 
RNAs identified in control and diseased OA ACL B) Principle component analysis 
revealed that small non-coding RNAs (sncRNA) between control and diseased ACL 
were distinctly grouped. C) Volcano plot demonstrate significant (FDR< 0.05) 
differentially expressed sncRNAs (red dots) with a fold-change of 1.4. D. Heatmap 
representation of the small non-coding RNA reads from control to OA ACL. Columns 
refer to the control and OA ACL samples and rows of miRNAs identified with their 
Ensembl identification. Heatmap was generated using log-transformed normalised 
read counts, normalisation was performed by EdgeR's trimmed mean of M values. 
The colour of each entry is determined by the number of reads, ranging from yellow 
(positive values) to red (negative values). 
 
 
Figure 2. Ingenuity Pathway Analysis (IPA) derived functions of differentially 
expressed  microRNAs in diseased osteoarthritic (OA) anterior cruciate 
ligament (ACL). A.  IPA identified that cellular functions differentiation of muscle, 
inflammation, proliferation, cell viability and fibrosis were associated with the 
differentially expressed microRNAs. Figures are graphical representations between 
molecules identified in our data in their respective networks. Red nodes, upregulated 
in OA, and green nodes, downregulated gene expression in OA. Intensity of colour is 
related to higher fold-change. Legends to the main features in the networks are shown. 
Functions colour is dependent on whether it is predicted to be activated or inhibited. 
B. Top network identified with canonical pathways overlaid for fibrosis, senescence, 
TGFβ signalling, RAR activation and PPAR/RXR activation.  
 
 
Figure 3. Osteoarthritis pathway targeted by predicted mRNA.  The canonical 
pathway for osteoarthritis signalling was highly ranked (p=2.33 E-23) using target 
mRNAs identified in Ingenuity Pathway Analysis (IPA) Targetscan from the 
differentially expressed miRNAs in diseased anterior cruciate ligaments (ACLs) 
derived from OA patients. The pathway was generated using IPA.  
 
 
Figure 4. Top-scoring networks derived from the 529 putative mRNAs 
differentially expressed in anterior cruciate ligaments (ACLs) derived from 
osteoarthritic (OA) joints. Ingenuity pathway analysis (IPA) identified A. ‘Cellular 
development, movement and genes expression’ with a scores of 41. (B) ‘Inflammatory 
disease, organismal injuries and abnormalities’ with a score of 35 and within this 
network are molecules linked to their respective canonical pathways. Both are overlaid 
with pertinent significant biological functions contained in the gene sets. Figures are 
graphical representations between molecules identified in our data and predicted 
mRNA targets in their respective networks. Green nodes, downregulated in ACLs from 
OA joints; red nodes, upregulated gene expression in ACLs from OA joints. Intensity 
of colour is related to higher fold-change. Key to the main features in the networks is 
shown. 
  
Figure 5. Gene ontology (GO) biological processes associated with 
dysregulated microRNAs targets were identified following TargetScan filter 
module using IPA. GO terms for biological process (FDR < 0.05) were summarized 
with ToppGene and visualised using REViGO and Cytoscape.  Boxes represent the 
main clusters of biological processes that were significantly influenced by dysregulated 
micrRNAs between control and diseased osteoarthritic (OA) anterior cruciate 
ligaments (ACLs).   
  
Supplementary Figures and Tables:  
 
 
 
Supplementary Figure 1. Age groups between control anterior cruciate ligament 
(ACL) samples and diseased OA ACL samples.  
Supplementary Figure 2. Heatmap representation of the differentially expressed 
snoRNAs and sncRNAs small non-coding RNA reads from control to OA anterior 
cruciate ligament (ACL)  
Supplementary Table 1. Donors’ age, gender and ethnicity information. 
Supplementary  Table 2. Differentially expressed sncRNAs between control and OA 
anterior cruciate ligament (ACL) samples with FDR<0.05 and reads greater than 10 
counts per million (CPM).  
 
Supplementary Table 3. Ingenuity Pathway Analysis (IPA) of differentially expressed 
microRNAs target genes between control and OA anterior cruciate ligament (ACL) and 
IPA of mRNA core analysis of putative mRNAs targets 
 
Supplementary Table 4. Gene ontology (GO) of the top biological processes gene 
ontology of putative mRNA targets between control and OA anterior cruciate ligament 
(ACL) summarised in REViGO tool.  
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